CVS Health (CVS)
(Delayed Data from NYSE)
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Zacks News
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $101.05 in the latest trading session, marking a +0.6% move from the prior day.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $102.26, marking a +1.57% move from the previous day.
The Zacks Analyst Blog Highlights Microsoft, CVS Health, Lockheed Martin, Berkshire Hathaway and Mitsubishi UFJ Financial Group
by Zacks Equity Research
Microsoft, CVS Health, Lockheed Martin, Berkshire Hathaway, and Mitsubishi UFJ Financial Group are part of The Zacks top Analyst Blog.
Top Research Reports for Microsoft, CVS Health & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), CVS Health (CVS) and Lockheed Martin (LMT).
Buckle (BKE) Benefits From Solid Sales & Online Business
by Zacks Equity Research
Buckle (BKE) reports higher sales and comparable store sales for August. BKE's men's and women's businesses continue to boost the top-line performance.
Company News for Sep 7, 2022
by Zacks Equity Research
Companies In The News Are: BBBY, SGFY, CVS, LOW, ILMN.
CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.
Will Business Momentum Aid Home Depot (HD) Amid Cost Woes?
by Zacks Equity Research
Home Depot (HD) looks well-poised on strength in Pro & DIY categories, robust housing market trends, digital momentum and ongoing investments despite cost woes.
Signet (SIG) Q2 Earnings Beat Estimates, Sales Fall Y/Y
by Zacks Equity Research
Signet (SIG) delivers better-than-estimated second-quarter fiscal 2023 results. However, sales fall from the year-ago fiscal quarter's level due to weak same-store sales.
Why Is CVS Health (CVS) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Big Lots' (BIG) Q2 Loss Narrower than Expected, Revenues Fall Y/Y
by Zacks Equity Research
Big Lots (BIG) reports a narrower-than-expected loss per share for second-quarter fiscal 2022. Also, comparable sales fall 9.2% in the quarter and hurt overall sales.
Best Buy's (BBY) Q2 Earnings Beat, Comparable Sales Fall 12.1%
by Zacks Equity Research
Best Buy (BBY) reports mixed second-quarter fiscal 2023 sales due to lower enterprise comparable sales.
J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli
by Zacks Equity Research
J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.
Urban Outfitters (URBN) Q2 Earnings Miss, Sales Improve Y/Y
by Zacks Equity Research
Urban Outfitters' (URBN) second-quarter fiscal 2023 earnings results reflect inflationary pressures from inbound freight expenses and transportation costs.
UnitedHealth (UNH) Eyes Signify Health Acquisition: Here's Why
by Zacks Equity Research
UnitedHealth (UNH) is reportedly the highest bidder with more than $30 per share for Signify Health.
Foot Locker (FL) Stock Up 20% on Q2 Earnings & Sales Beat
by Zacks Equity Research
Foot Locker (FL) posts better-than-expected earnings for second-quarter fiscal 2022. FL's FLX membership program and omni-channel capabilities appear encouraging.
CVS Health (CVS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CVS Health (CVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SpartanNash's (SPTN) Earnings Beat in Q2, Sales Rise Y/Y
by Zacks Equity Research
SpartanNash (SPTN) posts higher sales for the second quarter of 2022 on increased sales across all segments and solid comparable store sales.
This 1 Retail and Wholesale Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Lowe's (LOW) Q2 Earnings Beat Estimates, Sales Decline Y/Y
by Zacks Equity Research
Lowe's (LOW) reports a solid earnings performance for second-quarter fiscal 2022. A healthy operating margin backed by gains from the Total Home strategy aids the bottom line.
Home Depot (HD) Q2 Earnings Beat, Stock Down on Soft Margins
by Rajani Lohia
Home Depot's (HD) Q2 results reflect continued strong demand for home-improvement projects. HD's results represented the highest ever sales and earnings in its history.
The Zacks Analyst Blog Highlights Eli Lilly, CVS Health, Target, Chipotle Mexican Grill and FirstEnergy
by Zacks Equity Research
Eli Lilly, CVS Health, Target, Chipotle Mexican Grill and FirstEnergy are part of The Zacks top Analyst Blog.
Top Stock Reports for Eli Lilly, CVS Health & Target
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Eli Lilly and Company (LLY), CVS Health Corporation (CVS), and Target Corporation (TGT)
Has CVS Health (CVS) Outpaced Other Retail-Wholesale Stocks This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Dollar Tree (DLTR) have performed compared to their sector so far this year.